NEW YORK, March 19, 2018 /PRNewswire/ --WallStEquities.com strives to bring the best free research to the investment community.Today we are offering reports on AIMT, ATRA, AVXS, and AXSM which can be accessed for free by signing up to www.wallstequities.com/registration. For today, WallStEquities.com covers the Biotech industry, which consists of companies that are engaged
Brisbane, California headquartered Aimmune Therapeutics Inc.'s stock finished last Friday's session 2.01% lower at $31.65. A total volume of 2.02 million shares was traded, which was above their three months average volume of 922,370 shares. The Company's shares have advanced 43.47% over the past year. The stock is trading above its 200-day moving average by 11.93%. Additionally, shares of Aimmune Therapeutics, which develops and commercializes product candidates for the treatment of peanut and other food allergies, have a Relative Strength Index (RSI) of 39.84.
On March 07th, 2018, Aimmune Therapeutics announced that CEO Stephen Dilly, M.B.B.S., Ph.D. will present at the 17th Annual Needham Healthcare Conference on Tuesday, March 27th, 2018, at 4:30 p.m. ET in New York, NY. A live webcast of the presentation will be accessible on the Events page under the Investor Relations section of the Company's website. Get the full research report on AIMT for free by clicking below at:
On Friday, shares in Brisbane, California headquartered Atara Biotherapeutics Inc. ended the session flat at $41.90. The stock recorded a trading volume of 2.97 million shares, which was higher than its three months average volume of 1.07 million shares. The Company's shares have skyrocketed 185.03% in the previous three months and 124.66% over the past year. The stock is trading 15.78% above its 50-day moving average and 108.36% above its 200-day moving average. Moreover, shares of Atara Biotherapeutics, which focuses on developing therapeutics for the treatment of muscle wasting conditions and oncology, have an RSI of 52.93.
On February 21st, 2018, Atara Biotherapeutics (ATRA) announced that John McGrath, Executive Vice President and CFO, intends to retire from the Company as of April 27th, 2018. ATRA is initiating a search for its next CFO, who will play an instrumental leadership role in its continued evolution into a global commercial T?cell immunotherapy company.
On March 16th, 2018, research firm Guggenheim initiated a 'Neutral' rating on the Company's stock. Access the free research report on ATRA now by signing up at:
Bannockburn, Illinois headquartered AveXis Inc.'s shares dropped 2.50%, closing the session at $128.07. A total volume of 625,746 shares was traded, which was above their three months average volume of 518,930 shares. The stock has gained 10.79% in the last month, 30.23% over the previous three months, and 75.97% over the past year. The Company's shares are trading 8.72% and 29.79% above their 50-day and 200-day moving averages, respectively. Additionally, shares of the Company, which engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases, have an RSI of 55.71.
On February 27th, 2018, AveXis reported its results for the quarter and year ended December 31st, 2017. For Q4 2017, R&D expenses were $51.4 million, G&A expenses were $31.1 million, and net loss was $(81.7) million. For the full year, R&D expenses were $150.4 million, G&A expenses were $70.0 million, and net loss was $(218.1) million. Are you already registered with Wall St. Equities? Do so now for free, and get the report on AVXS at:
Last Friday, shares in New York-based Axsome Therapeutics Inc. recorded a trading volume of 324,408 shares. The stock ended the session 1.89% higher at $2.70. The Company's shares have advanced 3.85% in the past month. The stock is trading below its 50-day moving average by 10.80%. Furthermore, shares of Axsome Therapeutics have an RSI of 48.13.
On March 07th, 2018, Axsome Therapeutics reported its results for Q4 and year ended December 31st, 2017. For Q4 2017, R&D expenses were $4.5 million, G&A expenses were $2.0 million, and net loss was $(7.4) million. For the full year 2017, R&D expenses were $20.0 million, G&A expenses were $7.2 million, and net loss was $(28.9) million. Aspiring Member, please take a moment to register below for your free research report on AXSM at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/technical-perspectives-on-biotech-stocks----aimmune-therapeutics-atara-biotherapeutics-avexis-and-axsome-therapeutics-300615763.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Fallot's tetralogy is a rare and complex birth defect of the heart. Babies born with this condition ...
Bubonic plague is an infectious disease caused by the bacteria Yersinia pestis present in rodents ...
Steroids are miracle drugs but have to be used with caution. Some steroids are illegal to use, ...View All